OmniAb Inc. (OABI)
NASDAQ: OABIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OABI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $679.71M
- EPS (TTM)
- -$0.34
- Dividend yield
- None
- 52-week range
- 1.35 – 5.45
- Day range
- 4.61 – 5.05
- Volume / Avg
- 1.90M / 1.46M
- Beta
- —
- Shares outstanding
- 145.86M
52-week range
OABI stock today
On Nov 20, OABI ended the session at $4.66, shedding $0.37 (7.36%), versus the S&P 500's 3.70% decline. Shares are 14.5% below their 52-week high of $5.45, set on Nov 9, 2026 and 245.2% above the 52-week low of $1.35, near the top of the past year's range. OABI is up 151.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 163.3%.
OmniAb has posted a net loss over the last twelve months (EPS of -$0.34), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About OmniAb
Company profileOmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Mr. Matthew W. Foehr
- Headquarters
- EmeryVille, CA
- Employees
- 89
- IPO year
- 2021
- Website
- omniab.com
Financial highlights
Full financialsIn fiscal 2025, OmniAb generated $18.7 million in revenue, down 29.3% from fiscal 2024, its first annual decline since 2024. OmniAb reported a net loss of $64.8 million, compared with a loss of $62.0 million a year earlier. Operating margin was -369.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $18.67M | $26.39M | $34.16M | $59.08M | $34.75M |
| Growth | -29.27% | -22.75% | -42.17% | +70.02% | — |
| Net income | $-64.78M | $-62.03M | $-50.62M | $-22.33M | $-27.04M |
| EPS (diluted) | $-0.57 | $-0.61 | $-0.51 | $-0.26 | $-0.33 |
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$8.33+78.76%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 30, 2026
- EPS actual vs est.
- $-0.12 vs $-0.12
- Surprise
- 0.00%
OABI news
All OABI news- OmniAb (OABI) Q3 2026 Earnings Call TranscriptNasdaq
- OmniAb outlines $35M-$39M 2026 revenue outlook, backed by Eli Lilly deal and xPloration doubling planSeeking Alpha
- OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesNasdaqOABI, UTHR
- OmniAb GAAP EPS of -$0.12 beats by $0.01, revenue of $3.99M beats by $0.5MSeeking Alpha
- OmniAb Reports Third Quarter 2026 Financial Results and Business HighlightsBusiness Wire
- OmniAb to Report Third Quarter 2026 Financial Results on October 30Business Wire
- Pre-Market Most Active for Aug 17, 2026 : SNAP, NOK, OABI, SPCX, MUU, TQQQ, SQQQ, AAPL, PATH, BP, NWG, ORCLNasdaqSNAP, NOK, OABI, MUU
OmniAb peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRCNRC Health | 25.16 | +0.68% | $533.93M | vs OABI |
| MXCTMaxCyte Inc. | 1.37 | +7.03% | $141.45M | vs OABI |
| ABSIAbsci Corporation | 7.51 | -7.97% | $1.30B | vs OABI |
| ONMDOneMedNet Corp Class A | 4.70 | +4.21% | $29.15M | vs OABI |
| BIAFbioAffinity Technologies Inc. | 1.65 | -10.81% | $3.00M | vs OABI |
| ISPCiSpecimen Inc. | 0.4563 | -13.58% | $2.64M | vs OABI |
| ICLRICON plc | 186.71 | -1.92% | $13.99B | vs OABI |
| CRLCharles River Laboratories International Inc. | 314.32 | -4.15% | $15.06B | vs OABI |
Indexes, lists and sector
OmniAb stock FAQ
What is OmniAb's stock price today?
OABI last traded at $4.66 as of Nov 20, 4:00 PM EST, down 7.36% on the day. Prices are delayed at least 15 minutes.
Who is OmniAb's CEO?
Mr. Matthew W. Foehr is the chief executive officer of OmniAb Inc., which has about 89 employees.
What is the OABI 52-week high?
The 52-week high for OABI is $5.45 and the 52-week low is $1.35. The stock is currently 14.5% below its high.